email@example.com Contact Person Mr. Francisco Moris Products/Services Our Genetic Engineering and Combinatorial Biosynthesis technology in Natural Products enables the development of two experimental Natural Products hybrid drugs, now in regulatory preclinical development in oncology: EC-8042, a mithralog one order of magnitude less toxic than mithramycin, and the indolocarbazole EC-70124, a kinase inhibitor with unique activity and selectivity profile.
Contact Person Mr. Marc Parés Products/Services ESTEVE is a private international pharmaceutical group headquartered in Spain. Our portfolio covers key therapeutic areas such as CNS, Ophtha, Pain, CardioMetabolic and Respiratory. We are a partnership oriented company and we offer substantial expertise and successful experiences in our strategic alliances. Our R&D specializes in Analgesia, with products from Preclinical to Phase 3. In addition, we are developing Gene Therapies for rare diseases such as Type A Sanfilippo Syndrome.
Trademarks Xeristar, Zonegran, Prometax Patch, Zomarist, Alipza, Dafiro, Yantil Retard, Dormidina.